Dublin, Aug. 23, 2023 (GLOBE NEWSWIRE) -- The "Epidermolysis Bullosa Market Insights, Epidemiology and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.
Navigating the Landscape of Epidermolysis Bullosa: Unraveling Treatment Frontiers
Epidermolysis bullosa (EB), a rare and challenging disease, has emerged as a focal point in the medical landscape. Its rarity has earned it orphan drug status in many regions, offering incentives for research and development. Among the variants of EB, dystrophic epidermolysis bullosa (DEB) stands as particularly devastating, demanding urgent attention for effective treatment and management solutions.
Diverse Epidemiology and Treatment Spectrum
Different EB variants exhibit varying prevalence rates. In 2022, epidermolysis bullosa simplex accounted for over 60% of cases, while junctional epidermolysis bullosa constituted just 5%. Current therapeutic options primarily focus on wound care, pain and itch management, infection control, nutritional support, and managing associated complications. Stem cell-based therapies, like ABCB5+ mesenchymal stromal cells (ABCB5+ MSCs), have garnered attention for their immunomodulatory and anti-inflammatory attributes. Japan, a forerunner in cell therapies, achieved a landmark in 2018 by approving Autologous Cultured Epidermis (JACE) for EB treatment.
US Dominates the Market Landscape
In 2022, the US claimed the largest share in the EB market, with an approximate value of USD 1.3 billion, projected to grow by 2032. However, despite the availability of three approved therapies, there remains a substantial unmet need for EB patients in the US, EU, and Japan.
Pioneering Gene Therapies
Krystal's FDA-approved VYJUVEK marked a significant milestone in gene therapy for EB, targeting both recessive and dominant forms of the condition. Abeona Therapeutics has also made strides with EB-101, demonstrating positive Phase III results. Oleogel-S10, a topical gel containing a birch bark extract, is promising for junctional EB and dystrophic EB, with potential FDA approval.
Challenges and Opportunities
EB management heavily relies on wound care and symptomatic relief, demanding substantial time and cost. The pipeline presents promising avenues, such as JACE, FILSUVEZ, and more. Despite progress, substantial research and development efforts are still essential to enhance treatment options, ultimately enhancing the quality of life for EB patients worldwide.
Epidemiology and Drug Development Insights
The epidemiological perspective of EB unveils prevalent cases across regions. The US takes the lead, contributing to about 65% of total cases in the 7MM, followed by the EU4 and Japan. The emerging drug landscape features innovative gene therapies like EB-101, D-Fi, and more. Stem cell transplantation and gene therapy approaches are showing potential, with ongoing trials and approvals driving advancements.
Market Access and Reimbursement Dynamics
Market access and reimbursement play a pivotal role in the adoption of EB therapies. Payment models based on clinical outcomes and risk pools are being considered. Advocacy groups like DEBRA International aid in insurance and reimbursement processes, aiming to make treatment accessible and affordable.
Conclusion: Pioneering a New Era
The EB landscape is evolving with innovative therapies, pioneering gene treatments, and a growing understanding of patient needs. While challenges persist, the medical community's commitment to advancing treatment options remains unwavering. As research progresses and new therapies emerge, the future for EB patients holds the promise of improved quality of life and greater hope.
Key Topics Covered
1. Key Insights
2. Report Introduction
3. Executive Summary of Epidermolysis Bullosa (EB)
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Epidermolysis Bullosa Market Overview at a Glance
7. Epidermolysis Bullosa (EB): Disease Background and Overview
8. Treatment and Management of Epidermolysis Bullosa
9. Guidelines
10. Epidemiology and Patient Population of 7MM
11. Patient Journey
12. Marketed Drugs
13. Emerging Drugs
14. Epidermolysis Bullosa: 7MM Analysis
15. Unmet needs
16. SWOT Analysis
17. KOL Views
18. Market Access and Reimbursement
19. Appendix
A selection of companies mentioned in this report includes:
- Abeona Therapeutics
- Castle Creek Biosciences
- RHEACELL
- Ishin Pharma
- Holostem Terapie Avanzate
- BridgeBio (Phoenix Tissue Repair)
- InMed Pharmaceuticals
- Shionogi
- Anterogen
For more information about this report visit https://www.researchandmarkets.com/r/ex1xl2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
